Ignite Creation Date:
2024-05-06 @ 1:25 AM
Last Modification Date:
2024-10-26 @ 11:03 AM
Study NCT ID:
NCT01800630
Status:
COMPLETED
Last Update Posted:
2019-07-08
First Post:
2013-02-23
Brief Title:
Phase1 Study of Gemcitabine HCl Oral FormulationD07001-F4 in Patients With Advanced Solid Malignancies and Malignant Lymphomas
Sponsor:
Organization:
InnoPharmax Inc
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
37
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: